Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

A compound of formula (I)

• wherein
• A is selected from the group A-G1 consisting of N and CH;
• T is selected from the group T-G1 consisting of N, C—H, C—C1-4-alkyl, C—CHF2, C—CF3 and C—OCH3;
• R1 is selected from the group R1-G1 consisting of C1-3-alkyl;
• R2 is selected from the group R2-G1 consisting of a fused or spiro bicyclic ring system consisting of 1 N atom and 5 to 6 C atoms as ring members, wherein the ring system is attached via the N atom to the monocyclic heteroaromatic ring in formula (I) and wherein the ring system is optionally substituted with one substituent selected from the group consisting of F, C1-3-alkyl, CF3, CN, HO—C1-3-alkyl- and C1-3-alkyloxy- and wherein the ring system is optionally additionally substituted with one substituent selected from the group consisting of F and CH3;
• and
• R3 is selected from the group R3-G1 consisting of H, CH3, CHF2 or CF3,
• or a salt thereof.